MCB1 also mediates sorafenib/lenvatinib resistance by downregulating FGFR1 and VEGFR3 expression in a proteasome‐dependent manner and serves as a potential biomarker for individualized HCC therapy. This evidence concerns the gene PSMD4 and hepatocellular carcinoma.